Overall, pyrotinib, trastuzumab, and docetaxel as neoadjuvant treatment achieved a statistically significant and clinically meaningful improvement in the tpCR rate for patients with HER2-positive early or locally advanced breast cancer compared with placebo, trastuzumab, and docetaxel, with an acceptable safety profile, supporting the approval of this combination as a new neoadjuvant treatment option in China. This evidence concerns the gene ERBB2 and breast cancer.